100 research outputs found
M cells are involved in pathogenesis of human contact lens-associated giant papillary conjunctivitis
INTRODUCTION: The objective was to study the pathogenesis of contact lens-associated giant papillary conjunctivitis (CL-GPC). MATERIALS AND METHODS: Twenty-one biopsies of conjunctival giant papillae were obtained from soft contact lens wearers. The tissues were fixed in 4% paraformaldehyde and embedded in paraffin. Sections of 5 ”m thickness were used for studies of histology and immunohistochemistry of pan-B and pan-T cell distributions. RESULTS: Conjunctival epitheliums on the top of conjunctiva-associated lymphoid tissue typically lacked goblet cells. Lymphocytes from underlying lymphoid follicle were pressed into intra-epithelial âpocketsâ formed through epithelial invagination. Under the follicle-associated epithelium, pan-B cells were mostly gathered in the central folliclar area and intraepithelial pockets, while CD3-positive T cells were predominantly distributed in parafolliclar region, but only a few in the intraepithelial pockets. CONCLUSIONS: Membranous epithelial cells (M cells) play a key role in the pathogenesis of CL-GPC for the binding and translocation of antigen and pathogen
Correlated alterations in prostate basal cell layer and basement membrane
Our recent studies revealed that focal basal cell layer disruption (FBCLD)
induced auto-immunoreactions represented a contributing factor for human
prostate tumor progression and invasion. As the basement membrane surrounds and
attaches to the basal cell layer, our current study assessed whether FBCLD would
impact the physical integrity of the associated basement membrane. Paraffin
sections from 25-human prostate tumors were subjected to double
immunohistochemistry to simultaneously elucidate the basal cell layer and the
basement membrane with corresponding biomarkers. The physical integrity of the
basement membrane overlying FBCLD was examined to determine the extent of
correlated alterations. Of a total of 89 FBCLD encountered, 76 (85 %) showed
correlated alterations in the overlying basement membrane, which included
distinct focal disruptions or fragmentations. In the remaining 13 (15%) FBCLD,
the overlying basement membrane showed significant attenuation or reduction of
the immunostaining intensity. The basement membrane in all or nearly all ducts
or acini with p63 positive basal cells was substantially thicker and more
uniform than that in ducts or acini without p63 positive basal cells, and also,
a vast majority of the focal disruptions occurred near basal cells that lack p63
expression. These findings suggest that focal disruptions in the basal cell
layer and alterations in the basement membrane are correlated events and that
the physical and functional status of the basal cells could significantly impact
the physical integrity of the overlying basement membrane. As the degradation of
both the basal cell layer and the basement membrane is a pre-requisite for
prostate tumor invasion or progression, ducts or acini with focally disrupted
basal cell layer and basement membrane are likely at greater risk to develop
invasive lesions. Thus, further elucidation of the specific molecules and
mechanism associated with these events may lead to the development of a more
effective alternative for repeat biopsy to monitor tumor progression and
invasion
Flexible Low-Dose GnRH Antagonist Protocol Is Effective in Patients With Sufficient Ovarian Reserve in IVF
Gonadotropin-releasing hormone antagonist (GnRH-ant) has been shown to negatively influence endometrial receptivity. Reducing the GnRH-ant dose during controlled ovarian stimulation (COS) when using a GnRH-ant protocol may be beneficial to embryo implantation. However, whether or not the minimum daily GnRH-ant dose should be individualized remains uncertain. In this retrospective study, we aimed to elucidate the feasibility and effectiveness of moderately reducing the daily GnRH-ant dose to 0.125 mg, and then adjusting the dose to 0.25 mg based on subsequent luteinizing hormone (LH) levels. Of the 434 patients analyzed in this study, 209 received our new flexible low-dose GnRH-ant protocol (Group 1) and 225 received a conventional GnRH-ant protocol with a fixed daily dose of 0.25 mg (Group 2). Furthermore, 105 and 114 cycles from groups 1 and 2 received fresh embryo transfer. In Group 1, 30 patients whose dose of 0.125 mg GnRH-ant was adjusted according to their LH levels and 179 patients who received consistently low doses were further divided into subgroups 1 and 2, respectively. Neither the number of retrieved oocytes and available embryos nor the implantation rate, clinical pregnancy rate, and ongoing pregnancy rate significantly differed between the two groups. However, GnRH-ant dose and stimulation duration were much lower and shorter in Group 1 than in Group 2 (p < 0.05). Subgroup 1 exhibited higher basal follicle-stimulating hormone (FSH) and lower antral follicle count (AFC) than subgroup 2 significantly. The number of retrieved oocytes and available embryos were lower in subgroup 1 than in subgroup 2 (6.83 ± 3.28 vs. 11.83 ± 4.82, 2.93 ± 1.86 vs. 4.99 ± 3.46, respectively, p < 0.05), while more canceled cycles for pre-ovulation occurred in subgroup 1 than in subgroup 2 (3/30 vs. 1/179, p < 0.05). The results showed that the flexible low-dose GnRH-ant protocol was as effective as the conventional fixed-dose GnRH-ant protocol with 0.25 mg per day for most patients with normal ovarian reserve. This retrospective analysis and the small sample size are the main limitations of this study, and a large sample RCT will be carried out in the future
Uterine cytokine profiles after low-molecular-weight heparin administration are associated with pregnancy outcomes of patients with repeated implantation failure
IntroductionLow molecular-weight heparin (LMWH) plays a role in repeated implantation failure (RIF), but outcomes are controversial. LMWH can potentially modulate local immune responses associated with the establishment and maintenance of pregnancy. The study aimed to explore the effects of LWMH in uterine inflammatory cytokine profiles and pregnancy outcomes of patients with repeated implantation failure (RIF) but without thrombophilia.MethodsWe compared clinical characteristics and reproductive outcomes among 326 patients with RIF, but not thrombophilia, undergoing frozen embryo transfer (FET) cycle with or without LMWH treatment. Endometrium secretions were aspirated from both groups after 3 days of progesterone administration before and after LMWH treatment. Cytokine mRNA expression was analyzed in primary endometrial cells in vitro.ResultsThe clinical and ongoing pregnancy rates did not significantly differ between the groups (31.5% vs. 24.4%, p = 0.15; 29.6% vs. 20.7%, p = 0.06). Concentrations of IL-6 and granulocyte-colony stimulating factor (G-CSF) in uterine secretions were significantly increased in the LWMH group, regardless of pregnancy outcomes (P < 0.05). And, in all patients treated with LWMH, those of secreted IL-6, IL-15 and G-CSF were significantly increased in pregnant group (P < 0.05). The expression of mRNA for G-CSF and IL-6 was significantly increased in human endometrial stromal cells in vitro (P < 0.05) after stimulation with LWMH (10 IU/mL).ConclusionsUterine cytokine profiles after LMWH administration are associated with pregnancy outcomes and LMWH may be beneficial for patients with three implantation failures who do not have coagulation disorders
TAp63 Is a Master Transcriptional Regulator of Lipid and Glucose Metabolism
SummaryTAp63 prevents premature aging, suggesting a link to genes that regulate longevity. Further characterization of TAp63â/â mice revealed that these mice develop obesity, insulin resistance, and glucose intolerance similar to those seen in mice lacking two key metabolic regulators, Silent information regulator T1 (Sirt1) and AMPK. While the roles of Sirt1 and AMPK in metabolism have been well studied, their upstream regulators are not well understood. We found that TAp63 is important in regulating energy metabolism by accumulating in response to metabolic stress and transcriptionally activating Sirt1, AMPKα2, and LKB1, resulting in increased fatty acid synthesis and decreased fatty acid oxidation. Moreover, we found that TAp63 lowers blood glucose levels in response to metformin. Restoration of Sirt1, AMPKα2, and LKB1 in TAp63â/â mice rescued some of the metabolic defects of the TAp63â/â mice. Our study defines a role for TAp63 in metabolism and weight control
Thyroid hormone receptor regulates most genes independently of fibroblast growth factor 21 in liver
Thyroid hormone (TH) acts through specific receptors (TRs), which are conditional transcription factors, to induce fibroblast growth factor 21 (FGF21), a peptide hormone that is usually induced by fasting and that influences lipid and carbohydrate metabolism via local hepatic and systemic endocrine effects. While TH and FGF21 display overlapping actions when administered, including reductions in serum lipids, according to the current models these hormones act independently in vivo. In this study, we examined mechanisms of regulation of FGF21 expression by TH and tested the possibility that FGF21 is required for induction of hepatic TH-responsive genes. We confirm that active TH (triiodothyronine (T3)) and the TRÎČ-selective thyromimetic GC1 increase FGF21 transcript and peptide levels inmouse liver and that this effect requires TRÎČ. T3 also induces FGF21 in cultured hepatocytes and this effect involves direct actions of TRÎČ1, which binds a TRE within intron 2 of FGF21. Gene expression profiles of WT and Fgf21-knockout mice are very similar, indicating that FGF21 is dispensable for the majority of hepatic T3 gene responses. A small subset of genes displays diminished T3 response in the absence of FGF21. However, most of these are not obviously directly involved in T3-dependent hepatic metabolic processes. Consistent with these results, T3-dependent effects on serum cholesterol are maintained in the Fgf21-/- background and we observe no effect of the Fgf21-knockout background on serum triglycerides and glucose. Our findings indicate that T3 regulates the genes involved in classical hepatic metabolic responses independently of FGF21
Proteomics Analysis of Myocardial Tissues in a Mouse Model of Coronary Microembolization
Coronary microembolization (CME) is an important clinical problem, and it is related to poor outcome. The specific molecular mechanisms of CME are not fully understood. In the present study, we established a mice model of CME. Isobaric tags for relative and absolute quantitation (iTRAQ) and liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) technologies identified 249 differentially expressed proteins in the myocardial tissues of CME mice as compared with sham-operated mice. Bioinformatics analysis demonstrated that these differentially expressed proteins were enriched in several energy metabolism or cytoskeleton organization related processes or pathways. Quantitative PCR and Western blotting validation experiments revealed that succinate dehydrogenase (SDHA and SDHB) were upregulated, Rho GDP dissociation inhibitor α (RhoGDIα) and Filamin-A (FLNA) were downregulated significantly in CME mice. These findings indicated that the alternations of the cytoskeleton and energy metabolism pathways play important roles in the pathogenesis of CME, future studies are warranted to verify if targeting these molecules might be useful to alleviate CME injury or not
Androgens Regulate Prostate Cancer Cell Growth via an AMPK-PGC-1?-Mediated Metabolic Switch
Prostate cancer is the most commonly diagnosed malignancy among men in industrialized countries, accounting for the second leading cause of cancer-related deaths. While we now know that the androgen receptor (AR) is important for progression to the deadly advanced stages of the disease, it is poorly understood what AR-regulated processes drive this pathology. Here, we demonstrate that AR regulates prostate cancer cell growth via the metabolic sensor 5?-AMP-activated protein kinase (AMPK), a kinase that classically regulates cellular energy homeostasis. In patients, activation of AMPK correlated with prostate cancer progression. Using a combination of radiolabeled assays and emerging metabolomic approaches, we also show that prostate cancer cells respond to androgen treatment by increasing not only rates of glycolysis, as is commonly seen in many cancers, but also glucose and fatty acid oxidation. Importantly, this effect was dependent on androgen-mediated AMPK activity. Our results further indicate that the AMPK-mediated metabolic changes increased intracellular ATP levels and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1?)-mediated mitochondrial biogenesis, affording distinct growth advantages to the prostate cancer cells. Correspondingly, we used outlier analysis to determine that PGC-1? is overexpressed in a subpopulation of clinical cancer samples. This was in contrast to what was observed in immortalized benign human prostate cells and a testosterone-induced rat model of benign prostatic hyperplasia. Taken together, our findings converge to demonstrate that androgens can co-opt the AMPK-PGC-1? signaling cascade, a known homeostatic mechanism, to increase prostate cancer cell growth. The current study points to the potential utility of developing metabolic-targeted therapies directed towards the AMPK-PGC-1? signaling axis for the treatment of prostate cancer
- âŠ